Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
104 hedge funds and large institutions have $249M invested in Progenics Pharmaceuticals Inc in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 33 reducing their positions, and 29 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $262M → $249M (-$12.8M)
6% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 33
13% less funds holding
Funds holding: 120 → 104 (-16)
52% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 29
86% less call options, than puts
Call options by funds: $334K | Put options by funds: $2.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Pinnacle Associates
New York
|
+$13.7M |
| 2 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$1.93M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.16M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.04M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$617K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.51M |
| 2 |
Millennium Management
New York
|
-$1.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$1.84M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.81M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.66M |
PGNX Hedge Fund Activity: Q2 2016 in Review
104 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2016, worth a combined $249M — down 4.9% from $262M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PGNX and 14 opened new positions — a net loss of 15 holders — while 33 trimmed existing stakes and 31 added.
The largest buyer was Pinnacle Associates, opening a new position worth an estimated $13.7M. The largest seller was Fidelity Investments, cutting an estimated $4.51M.
- 104 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2016, down from 120 in Q1 2016.
- Funds reported $249M of Progenics Pharmaceuticals Inc stock for Q2 2016, down 4.9% quarter-over-quarter.
- 14 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2016 and 29 closed out, a net change of -15 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q2 2016 was Pinnacle Associates, an estimated $13.7M added.
- The largest Progenics Pharmaceuticals Inc seller in Q2 2016 was Fidelity Investments, an estimated $4.51M sold.
Based on aggregated 13F filings for Q2 2016.